Lead PI: Professor Chris Bladin
Status: Site Selection
No. of Patients Currently Recruited: 0 No. of Patients Required: 528
Phase 2, multicentre, prospective, randomised, open label, blinded end-point (PROBE) trial with pre-planned adaptive sample size re-estimation. 10 sites anticipated to randomise 528 (1:1 ratio) patients by 2019. Primary Hypothesis: Treatment with short acting Exenatide (Byetta) in patients with acute ischaemic stroke will improve neurological outcome as measured by >8 point improvement in NIHSS stroke disability score (or NIHSS 0-1) at 7 days.
Trial URL:
